119 related articles for article (PubMed ID: 2905936)
1. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
[TBL] [Abstract][Full Text] [Related]
2. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan MY; Stambuk D
Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
[TBL] [Abstract][Full Text] [Related]
3. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
Lin JH; Chremos AN; Yeh KC; Antonello J; Hessey GA
Eur J Clin Pharmacol; 1988; 34(1):41-6. PubMed ID: 2896129
[TBL] [Abstract][Full Text] [Related]
4. [Famotidine treatment of patients with gastric and duodenal ulcers. A comparative study with once or twice-a-day administration].
Bonardelli P; Fujita Y; Fujita R; Sugata F
Clin Ter; 1987 Aug; 122(3):183-7. PubMed ID: 2904317
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics of famotidine in man.
Kroemer H; Klotz U
Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
[TBL] [Abstract][Full Text] [Related]
6. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and dynamics of famotidine in patients with renal failure.
Gladziwa U; Klotz U; Krishna DR; Schmitt H; Glöckner WM; Mann H
Br J Clin Pharmacol; 1988 Sep; 26(3):315-21. PubMed ID: 2902874
[TBL] [Abstract][Full Text] [Related]
9. Stability of famotidine in commonly used nutritional infusion fluids.
Underberg WJ; Koomen JM; Beijnen JH
J Parenter Sci Technol; 1988; 42(3):94-7. PubMed ID: 2905734
[No Abstract] [Full Text] [Related]
10. Impaired bioavailability of famotidine given concurrently with a potent antacid.
Barzaghi N; Gatti G; Crema F; Perucca E
J Clin Pharmacol; 1989 Jul; 29(7):670-2. PubMed ID: 2569486
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.
Lameire N; Rosenkranz B; Brockmeier D
Scand J Gastroenterol Suppl; 1988; 146():100-10. PubMed ID: 2906455
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease.
Kamada T; Hata J; Kusunoki H; Sugiu K; Ito M; Tanaka S; Kawamura Y; Chayama K; Haruma K
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():99-104. PubMed ID: 15943855
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
Eley T; Luo FR; Agrawal S; Sanil A; Manning J; Li T; Blackwood-Chirchir A; Bertz R
J Clin Pharmacol; 2009 Jun; 49(6):700-9. PubMed ID: 19395585
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
[TBL] [Abstract][Full Text] [Related]
16. A single nocte dose of famotidine in the treatment of duodenal ulcer.
Qureshi H; Ahmad W; Zuberi SJ
J Pak Med Assoc; 1989 Apr; 39(4):104-6. PubMed ID: 2568508
[TBL] [Abstract][Full Text] [Related]
17. Famotidine has no significant effect on gonadal function in man.
Savarino V; Giusti M; Scalabrini P; Bessarione D; Magnolia MR; Percario G; Celle G
Gastroenterol Clin Biol; 1988 Jan; 12(1):19-22. PubMed ID: 3127266
[TBL] [Abstract][Full Text] [Related]
18. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.
Ariano RE; Fine A; Sitar DS; Rexrode S; Zelenitsky SA
Am J Kidney Dis; 2005 Oct; 46(4):681-7. PubMed ID: 16183423
[TBL] [Abstract][Full Text] [Related]
19. Effect of the H2 histamine receptor antagonist on oxygen metabolism in some morphotic blood elements in patients with ulcer disease.
Kedziora-Kornatowska K; Tkaczewski W; Blaszczyk J; Buczynski A; Chojnacki J; Kedziora J
Hepatogastroenterology; 1998; 45(19):276-80. PubMed ID: 9496526
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.
Inotsume N; Nishimura M; Fujiyama S; Sagara K; Sato T; Imai Y; Matsui H; Nakano M
Eur J Clin Pharmacol; 1989; 36(5):517-20. PubMed ID: 2568929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
